NICE tuned down the GLP-1 agonist earlier this year, but changed its stance after Novo Nordisk ... s third quarter results statement, which showed modest 3% growth for Saxenda in the first nine ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback